The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesCharacterization of leukaemias and lymphomas in human lysed whole peripheral blood or mononuclear cells separated by density gradient.
Childhood ALL prognosis (patients CD10+ have a better prognosis than CD10-)
CD10(FITC) / CD19 (PE) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.
10µl ofCD10(FITC) / CD19 (PE) is sufficient for labelling 1x106 cells.
RelevanceThe CD10 antigen (Mw = 100kDa) or "Common Acute Lymphoblastic Leukaemia Antigen" (CALLA) is expressed on the majority of B lymphoid leukaemias. It is also present on a wide variety of normal and neoplastic cell types including renal epithelium, fibroblasts, granulocytes, pre B and pre T cells, and some neural cells and neoplastic cell types including lymphomas and melanomas. It is a cell surface enzyme with endopeptidase activity.
CD19 antigen (MW = 95kDa) is present on 10-15% of human peripheral blood lymphocytes and approximately 60% of splenic lymphocytes. It is not expressed on T lymphocytes, granulocytes, activated T cells or monocytes. Moreover, CD19 is present on principal acute and chronic B cell leukemias and lymphomas.
Cellular localizationCD10: Membrane; single pass type II membrane protein.
CD19: Membrane; single pass type I membrane protein.